ATE312613T1 - Niedrig dosierte entecavir formulierung und deren verwendung - Google Patents

Niedrig dosierte entecavir formulierung und deren verwendung

Info

Publication number
ATE312613T1
ATE312613T1 AT01955090T AT01955090T ATE312613T1 AT E312613 T1 ATE312613 T1 AT E312613T1 AT 01955090 T AT01955090 T AT 01955090T AT 01955090 T AT01955090 T AT 01955090T AT E312613 T1 ATE312613 T1 AT E312613T1
Authority
AT
Austria
Prior art keywords
low dose
dose entecavir
entecavir formulation
formulation
low
Prior art date
Application number
AT01955090T
Other languages
English (en)
Inventor
Richard J Colonno
Omar L Sprockel
Abizer Harianawala
Divyakant Desai
Michael G Fakes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE312613(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE312613T1 publication Critical patent/ATE312613T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01955090T 2000-02-29 2001-01-26 Niedrig dosierte entecavir formulierung und deren verwendung ATE312613T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (1)

Publication Number Publication Date
ATE312613T1 true ATE312613T1 (de) 2005-12-15

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955090T ATE312613T1 (de) 2000-02-29 2001-01-26 Niedrig dosierte entecavir formulierung und deren verwendung

Country Status (35)

Country Link
US (1) US6627224B2 (de)
EP (2) EP1267880B2 (de)
JP (3) JP5140222B2 (de)
KR (1) KR100757155B1 (de)
AR (1) AR027965A1 (de)
AT (1) ATE312613T1 (de)
AU (1) AU2001229775A1 (de)
BG (1) BG65815B1 (de)
BR (1) BRPI0108435B8 (de)
CA (1) CA2401569C (de)
CO (1) CO5261593A1 (de)
CZ (1) CZ303395B6 (de)
DE (1) DE60115870T3 (de)
DK (1) DK1267880T4 (de)
EA (1) EA006181B1 (de)
EE (1) EE05442B1 (de)
EG (1) EG24408A (de)
ES (1) ES2253403T5 (de)
GE (1) GEP20053504B (de)
HK (1) HK1048771A1 (de)
HR (1) HRP20020649A2 (de)
HU (1) HU230698B1 (de)
IL (1) IL150447A0 (de)
MX (1) MXPA02008359A (de)
MY (1) MY127422A (de)
NO (1) NO324014B1 (de)
NZ (1) NZ520024A (de)
PE (1) PE20020770A1 (de)
PL (1) PL201411B1 (de)
RS (1) RS51561B (de)
SI (1) SI1267880T2 (de)
SK (1) SK288008B6 (de)
TW (1) TWI287988B (de)
UA (1) UA84534C2 (de)
WO (1) WO2001064221A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1267880T2 (sl) * 2000-02-29 2010-04-30 Bristol Myers Squibb Co Formulacija z nizko dozo entekavirja in uporaba
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP2433941A1 (de) * 2002-12-11 2012-03-28 Bristol-Myers Squibb Company Verfahren zur Isolierung des antiviralen Mittels [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylencyclopentyl]-6H-purin-6-one
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ES2596827T3 (es) 2003-11-17 2017-01-12 Biomarin Pharmaceutical Inc. Tratamiento de la fenilcetonuria con BH4
KR20060125805A (ko) * 2003-11-18 2006-12-06 베링거 인겔하임 인터내셔날 게엠베하 고체 약제학적 제제 형태
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
US20060127451A1 (en) * 2004-09-23 2006-06-15 Michael Augello Coating composition
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2010315414B2 (en) * 2009-10-28 2015-07-09 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
EA201290556A1 (ru) * 2009-12-23 2013-01-30 Рациофарм Гмбх Оральная лекарственная форма, включающая энтекавир
EP2536411A4 (de) * 2010-02-18 2013-08-07 Univ Princeton Hemmer des stoffwechsels langkettiger und sehr langkettiger fettsäuren als antiviruswirkstoffe mit breitem spektrum
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
EP2508172A1 (de) 2011-04-06 2012-10-10 Zentiva, a.s. Stabile und gleichförmige Formulierungen von Entecavir und Herstellungsverfahren dafür
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
IN2011CH03893A (de) * 2011-11-14 2015-08-21 Hetero Research Foundation
EP2644197A1 (de) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Neue pharmazeutische Zusammensetzungen enthaltend Entecavir
EP2644196B1 (de) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmazeutische Zusammensetzungen enthaltend Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
WO2015194923A1 (ko) * 2014-06-20 2015-12-23 주식회사 씨티씨바이오 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법
US11273129B2 (en) 2015-09-30 2022-03-15 Daicel Corporation Particle composition for easy-to-use solid preparation and easy-to-use solid preparation including said particle composition
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
DE19714024A1 (de) * 1996-04-04 1997-11-20 L A B Ges Fuer Pharmakologisch Verfahren zur Herstellung von gering dosierten freifließenden und/oder direktkomprimierbaren Pulversystemen
AU4090697A (en) 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
ES2255295T3 (es) * 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) † 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
SI1267880T2 (sl) * 2000-02-29 2010-04-30 Bristol Myers Squibb Co Formulacija z nizko dozo entekavirja in uporaba

Also Published As

Publication number Publication date
EE200200484A (et) 2004-04-15
UA84534C2 (uk) 2008-11-10
BG106905A (bg) 2003-04-30
JP5921746B2 (ja) 2016-05-24
EE05442B1 (et) 2011-08-15
MXPA02008359A (es) 2003-02-12
JP2004503467A (ja) 2004-02-05
DE60115870T2 (de) 2006-08-17
GEP20053504B (en) 2005-05-10
BR0108435A (pt) 2004-06-15
US6627224B2 (en) 2003-09-30
EP1267880A1 (de) 2003-01-02
BG65815B1 (bg) 2010-01-29
NO20024099L (no) 2002-08-28
ES2253403T5 (es) 2010-04-22
PE20020770A1 (es) 2002-09-06
HU230698B1 (hu) 2017-09-28
HK1048771A1 (zh) 2003-04-17
NO324014B1 (no) 2007-07-30
PL201411B1 (pl) 2009-04-30
EP1267880B2 (de) 2010-01-20
NZ520024A (en) 2005-03-24
SK11652002A3 (sk) 2003-09-11
JP5140222B2 (ja) 2013-02-06
DE60115870D1 (de) 2006-01-19
EA200200812A1 (ru) 2003-12-25
MY127422A (en) 2006-11-30
DK1267880T3 (da) 2006-03-06
YU63002A (sh) 2005-03-15
EG24408A (en) 2009-05-20
JP2012255017A (ja) 2012-12-27
RS51561B (sr) 2011-08-31
CO5261593A1 (es) 2003-03-31
AR027965A1 (es) 2003-04-16
SI1267880T2 (sl) 2010-04-30
WO2001064221A1 (en) 2001-09-07
BRPI0108435B1 (pt) 2019-02-05
DE60115870T3 (de) 2010-07-29
AU2001229775A1 (en) 2001-09-12
IL150447A0 (en) 2002-12-01
HUP0500558A3 (en) 2012-08-28
SK288008B6 (sk) 2012-10-02
DK1267880T4 (da) 2010-05-17
TWI287988B (en) 2007-10-11
EP1642582A1 (de) 2006-04-05
NO20024099D0 (no) 2002-08-28
KR20020082230A (ko) 2002-10-30
ES2253403T3 (es) 2006-06-01
CA2401569C (en) 2009-08-18
EP1267880B1 (de) 2005-12-14
HUP0500558A2 (hu) 2005-09-28
HRP20020649A2 (en) 2004-12-31
CZ303395B6 (cs) 2012-08-29
EA006181B1 (ru) 2005-10-27
JP2015178523A (ja) 2015-10-08
SI1267880T1 (sl) 2006-06-30
KR100757155B1 (ko) 2007-09-07
BRPI0108435B8 (pt) 2021-05-25
CA2401569A1 (en) 2001-09-07
PL366102A1 (en) 2005-01-24
US20010033864A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
ATE312613T1 (de) Niedrig dosierte entecavir formulierung und deren verwendung
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60138768D1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
ATA13842001A (de) Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60010538D1 (de) Kosmetische Tensid-Präparate und deren Verwendung
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung
ATE300525T1 (de) Uracilverbindungen und deren verwendung
ATE381329T1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
PL372322A1 (en) Low dose liquid entecavir formulations and use
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE60109397D1 (de) Alkyl-substituierte Derivate von 4,5,6,7-Tetrahydro-4-indan und deren Verwendung in Parfümzubereitungen
DE60013191D1 (de) Tensidzusammensetzung und deren Verwendung
HK1040196A1 (zh) 低劑量艾替開韋製劑及其應用
DE60125374D1 (de) Bisacrylamid enthaltende dentalmassen und deren verwendung
DE10049596B4 (de) Dielektrische Keramikzusammensetzung und deren Verwendung
DE60036885D1 (de) Succinimidverbindungen und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267880

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1267880

Country of ref document: EP